OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost acquired 125,000 shares of the business's stock in a transaction that occurred on Friday, December 13th. The stock was purchased at an average cost of $1.59 per share, with a total value of $198,750.00. Following the acquisition, the chief executive officer now directly owns 212,536,477 shares of the company's stock, valued at $337,932,998.43. This trade represents a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Wednesday, December 11th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.56 per share, with a total value of $780,000.00.
- On Friday, November 29th, Phillip Md Et Al Frost purchased 199,072 shares of OPKO Health stock. The stock was acquired at an average price of $1.53 per share, for a total transaction of $304,580.16.
- On Friday, November 22nd, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The stock was bought at an average price of $1.59 per share, with a total value of $159,000.00.
- On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were bought at an average price of $1.62 per share, for a total transaction of $162,000.00.
- On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The stock was bought at an average price of $1.50 per share, with a total value of $420,274.50.
OPKO Health Stock Down 1.2 %
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing | Ad
Biden broke it... Now Trump is going to fix it.
Starting with "Exec. Order 001."
I put all the details together for you here — but please hurry.
NASDAQ OPK opened at $1.59 on Friday. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.76. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.09 billion, a PE ratio of -8.37 and a beta of 1.62. The stock's 50 day moving average is $1.53 and its 200 day moving average is $1.47.
Hedge Funds Weigh In On OPKO Health
Several hedge funds have recently modified their holdings of OPK. Comerica Bank lifted its position in shares of OPKO Health by 125.0% in the first quarter. Comerica Bank now owns 90,000 shares of the biotechnology company's stock worth $108,000 after buying an additional 50,000 shares in the last quarter. CIBC Asset Management Inc boosted its position in shares of OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 8,978 shares during the last quarter. PFG Investments LLC grew its holdings in shares of OPKO Health by 2.5% in the second quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company's stock valued at $1,201,000 after purchasing an additional 23,700 shares in the last quarter. American Century Companies Inc. bought a new stake in OPKO Health in the second quarter worth $112,000. Finally, Y.D. More Investments Ltd purchased a new stake in OPKO Health during the second quarter valued at $1,840,000. Hedge funds and other institutional investors own 64.63% of the company's stock.
Analysts Set New Price Targets
A number of research analysts recently issued reports on the company. Barrington Research reiterated an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th. HC Wainwright reiterated a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research report on Thursday, September 26th. Finally, Piper Sandler restated an "overweight" rating and set a $3.00 price objective on shares of OPKO Health in a research report on Tuesday, September 17th.
Get Our Latest Analysis on OPKO Health
OPKO Health Company Profile
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
